Black Diamond Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good morning. Welcome to the 41st JPMorgan Healthcare Conference and the last day of the conference. I hope you have enjoyed all the presentations.
My name is Ting Zhang. I am from the JPMorgan Healthcare Investment Banking team. It is my great pleasure to introduce the session speaker, David Epstein, CEO of Black Diamond Therapeutics.
Without further ado, I'd like the company to take it away.
Thank you. And good morning, everybody, and welcome to the last day of JPMorgan. So I want to remind everybody that this presentation contains forward-looking statements about Black Diamond Therapeutics, particularly our therapeutics programs, our discovery programs, and our use of cash going forward.
So Black Diamond Therapeutics is a clinical-stage precision oncology medicine company, and 2023 is going to be a catalyst-rich year for the company. I'll remind you that BDTX-1535 is a proprietary EGFR MasterKey inhibitor
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |